EIF eiffel technologies limited

is this company beginning a strong rally

  1. 80 Posts.

    DIrectors of Eiffel Technologies Limited (ASX: EIF) are pleased
    to announce that the Company has signed an agreement for its core
    technology with a major pharmaceutical company. Under the terms of
    the agreement Eiffel is forbidden to discuss the terms until
    preliminary research work is completed which is expected to be four
    to five months. This agreement follows Eiffel's current alliances
    with Profile Therapeutics, BattellePharma Inc, Amarin and Aradigm

    In addition, the Company continues to build its intellectual property
    portfolio and in mid April filed a further international patent
    relating to the application of its particle re-engineering
    technologies. To date, the Company has filed 7 international and
    provisional patent applications.

    The Company also announce that they have appointed US based Global
    Markets Capital Corporation to assist with its NASDAQ ADR listing.
    Global Markets Capital specialises in introducing Australian based
    listed companies to US institutions and high net worth investors.
    Eiffel Technologies recently completed its first investor "Road Show"
    in New York and further investment activities are planned over the
    coming year. The Company is pleased with this association as Global
    Markets Capital has an excellent track record in assisting
    Australian-listed companies access the US capital markets.

    Mr Mark Saunders, President of Global Markets Capital, said that the
    drug delivery market is projected to grow to US$100 billion by 2005
    and is currently the highest growth area in the pharmaceutical
    industry. According to Mr Saunders, "approximately half of currently
    prescribed pharmaceuticals on the market have absorption problems and
    a third of new drugs have formulation problems when they go into
    production". The value of Eiffel's SCF Technology will be well
    recognized by the US capital markets, particularly considering the
    recent acquisitions of three of the leaders in the SCF industry,
    Separex, Bradford Particle Design, and RTP Pharma.

    In the medium term, Global Markets Capital will advise Eiffel
    Technologies on the merits and timing for a NASDAQ listing. Global
    Markets Capital is a leading advisor to non-US companies establishing
    American Depositary Receipt programs and has managed the NASDAQ
    listing process for many companies.

    Eiffel Technologies Limited, is a bioengineering company focused on
    improving the performance and delivery of pharmaceuticals. Based in
    Melbourne, Australia, the Company is developing and commercializing a
    range of drug re-engineering platforms to improve drug performance,
    extend patent life and effectively deliver new and currently marketed
    pharmaceuticals. Eiffel Technologies' research programme focuses on
    the improving drugs in a range of therapeutic areas, including
    diabetes, asthma, cardiovascular and anti-inflammatory disease. For
    more information on Eiffel Technologies, please visit the Company's
    website at www.eiffeltechnologies.com.au.

watchlist Created with Sketch. Add EIF (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.